AKYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AKYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Akoya Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 was $116.34 Mil. Akoya Biosciences's Total Assets for the quarter that ended in Sep. 2024 was $129.97 Mil. Therefore, Akoya Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 was 0.90.
The historical data trend for Akoya Biosciences's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akoya Biosciences Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Liabilities-to-Assets | 1.34 | 1.66 | 0.36 | 0.67 | 0.70 |
Akoya Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.65 | 0.70 | 0.79 | 0.85 | 0.90 |
For the Medical Instruments & Supplies subindustry, Akoya Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Akoya Biosciences's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Akoya Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Liabilities-to-Assets (A: Dec. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 126.599 | / | 180.369 | |
= | 0.70 |
Akoya Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 is calculated as
Liabilities-to-Assets (Q: Sep. 2024 ) | = | Total Liabilities | / | Total Assets |
= | 116.34 | / | 129.973 | |
= | 0.90 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akoya Biosciences (NAS:AKYA) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Akoya Biosciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Mckelligon | director, officer: President/CEO | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Frederic Pla | officer: Chief Operating Officer | C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700 |
Goldman Myla Lai | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
John Frederick Ek | officer: Chief Financial Officer | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Scott Mendel | director | 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008 |
Matthew Winkler | director | C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744 |
Thomas A. Raffin | director, 10 percent owner | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010 |
Robert G Shepler | director | |
Jennifer Kamocsay | officer: General Counsel | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762 |
Joseph Driscoll | officer: Chief Financial Officer | 5 DICARLO ROAD, HOPKINTON MA 01748 |
Nolan Garry Ph.d. | director | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Thomas P Schnettler | director | 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020 |
Ehab El-gabry | officer: Chief Medical Officer | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Marilee Moy | officer: Chief People Officer | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Ramachandran Niro Ph.d | officer: Chief Business Officer | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
From GuruFocus
By GuruFocus Research • 08-05-2024
By Marketwired • 07-15-2024
By Marketwired • 10-28-2024
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-13-2024
By GuruFocus News • 11-15-2024
By Marketwired • 05-06-2024
By GuruFocus Research • 08-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.